Ticker: TSX - TOS
Shares Outstanding: 65,884,682
QUÉBEC CITY, June 28, 2012 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, restates that the Company is actively engaged in the process for clearance of the STERIZONE® 125L+ Sterilizer. As part of the normal review process pertaining to the recently submitted file for clearance of its new sterilizer, TSO3 has had follow-up communications with the US regulatory agency.
"It is not our practice to disclose about the ongoing regulatory process, but as this topic is of great interest to the investment community, we feel that it is appropriate to update through formal disclosure", stated R.M. (Ric) Rumble, President and CEO of TSO3. "Obtaining clearance to sell in the United States remains our top priority. Our recent communications with the agency were positive and productive and we are confident in a positive outcome. We will not comment on details of the discussions", concluded Mr. Rumble.
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
For further information:
Source: TSO3 Inc.
Director - Investor and Business Relations
(418) 651-0003, Ext. 237
Email: [email protected]